HIGH RATE OF HEPATITIS B VIRUS MOTHER-TO-CHILD TRANSMISSION IN LAO PEOPLE S DEMOCRATIC REPUBLIC

Similar documents
SEROPREVALENCE OF HEPATITIS B AND C VIRUS INFECTIONS AMONG LAO BLOOD DONORS

Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis

Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida

HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board

Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.

HEPATITIS B: PREGNANCY AND LABOR MANAGEMENT MICHAEL P. NAGEOTTE, M.D.

Viral Hepatitis in Reproductive Health

AN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS

Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand

Hepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature

Summary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017

Effect of elective cesarean section on the risk of mother-to-child transmission of hepatitis B virus

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases

Epidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur

Hepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia

Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees

HBsAg(+) mothers is a transient

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Seroprotection after Hepatitis B Vaccination among Newborn Infants: a Review

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

Chapter 2 Hepatitis B Overview

Media centre. WHO Hepatitis B. Key facts. 1 of :12 AM.

Should we treat hepatitis B positive pregnant women to prevent mother to child transmission?

Perinatal Hepatitis b Prevention

Hepatitis B (Hep-B) is one of the most

Chapter 5 Serology Testing

HEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011

Summary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background:

HBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of

Perinatal Hepatitis B Prevention Program. Purpose

Hepatitis B virus in the Lao People s Democratic Republic: a cross sectional serosurvey in different cohorts

Management of Chronic Hepatitis B in Asian Americans

The Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections

Confirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).

Seroprevalence of Hepatitis B Surface Antigen (HBsAg) Among Patients at a Tertiary Care Hospital in Mumbai, India

Hepatitis B and Hepatitis B Vaccine

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Viral Hepatitis Diagnosis and Management

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

NHS public health functions agreement Service specification No.1 Neonatal hepatitis B immunisation programme

Hepatitis and pregnancy

Hepatitis B virus (HBV) infection is an important. Brief Communication

STATE TDAP VACCINE PROGRAM

universal vaccination

Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination

Supplementary Appendix

HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium

in pregnancy Document Review History Version Review Date Reviewed By Approved By

Blood-Borne Viruses and Pregnancy. Prof Ashley Brown Imperial Healthcare NHS Trust

WPR/RC68/7 page 7 ANNEX

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

PERINATAL HEPATITIS B

The hexavalent DTaP/IPV/Hib/HepB combination vaccine

Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011

EAST LONDON INTEGRATED CARE

Hepatitis B infection

Viral Hepatitis B and C in North African Countries

MA PERINATAL HEPATITIS B PREVENTION PROGRAM

Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific

Hepatitis B vaccination worldwide: Lessons learnt and the way forward

SEROLOGICAL SURVEY OF VIRAL HEPATITIS A, B, AND C AT THAI CENTRAL REGION AND BANGKOK: A POPULATION BASE STUDY

A VIEW OF DEMOGRAPHIC FACTORS OF HEPATITIS B VIRUS INFECTION IN DURRES REGION DURING

Global Epidemiology and Prevention of Hepatitis B

NHS public health functions agreement

Treatment of hepatitis B : the guidelines and real life

The hexavalent DTaP/IPV/Hib/HepB combination vaccine

Hepatitis B at a Glance

HEPATITIS B: are escape mutants of concern?

Management of Viral Infection during Pregnancy

International Journal of Pharma and Bio Sciences DETECTION OF HEPATITIS B SURFACE ANTIGEN USING ELISA AND REAL TIME PCR ABSTRACT

Effect of HBIG combined with hepatitis B vaccine on blocking HBV transmission between mother and infant and its effect on immune cells

OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program

Current recommendations of managing HBV infection in preconception or pregnancy

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

REPORT THIRD EXPERT WORKING GROUP MEETING ON HEPATITIS B. Tokyo, Japan 6-7 March Convened by:

Chronic Hepatitis B in Pregnancy

Epidemiology of hepatitis B and D in Greece

Test Name Results Units Bio. Ref. Interval

Hepatitis B Vaccination among Physicians, Dentists and Nurses in Bahrain

Anti-HBc: state of the art what is the CORE of the issues?

Hepatitis B Virus in Pregnancy

Test Name Results Units Bio. Ref. Interval

Management of Hepatitis B - Information for primary care providers

Carrier state and chronic infection state. At-risk populations

The Alphabet Soup of Viral Hepatitis Testing

Integrated Hepatitis B prevention in PMTCT program in Chamanculo maternity Maputo, Mozambique

HBV PUBLIC HEALTH IMPLICATIONS

Increase Hepatitis B Screening and Vaccinations

Hepatitis B Positive: Care of Mother Policy

A study on hepatitis-b in pregnant women and their neonatal outcome

Prevention and control of perinatal transmission of hepatitis B and C VIENNA, AUSTRIA 1-2 June 2017

Mathematical Model of Hepatitis B in. the Bosomtwe District of Ashanti Region, Ghana

Yakima Health District BULLETIN

Prevention of Infections in Mothers & Infants

Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges

REVIEW PRIORITIES AND CHALLENGES FOR HEPATITIS B CONTROL IN THE PHILIPPINES AND THE IMPORTANCE OF A VACCINE DOSE AT BIRTH

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

Transcription:

HIGH RATE OF HEPATITIS B VIRUS MOTHER-TO-CHILD TRANSMISSION IN LAO PEOPLE S DEMOCRATIC REPUBLIC Prapan Jutavijittum 1, Amnat Yousukh 1, Bounnack Saysanasongkham 2, Bounthome Samountry 3, Khamtim Samountry 4, Kan Toriyama 5, Masaaki Tokuda 6, Hirohito Yoneyama 7 and Tsutomu Masaki 7 1 Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 2 Mother and Child Hospital, Vientiane; 3 Department of Pathology, Faculty of Basic Sciences, 4 Department of Medicine, Faculty of Medicine, University of Health Sciences, Ministry of Public Health, Vientiane, Lao PDR; 5 Department of Pathology, Japanese Red-Cross Nagasaki Atomic Bomb Hospital, Nagasaki; 6 Department of Cell Physiology, 7 Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan Abstract. Hepatitis B virus infection is endemic in Lao People s Democratic Republic (PDR). Among 3,000 pregnant women attending an antenatal clinic at Mother and Child Hospital in Vientiane, Lao PDR, 5.8% were HBsAg positive by a rapid test. Among serum samples of 47 infants aged 9-12 months born to HBsAg-positive mothers, 38% were anti-hbs negative. Percent anti-hbs negative children is significantly higher in those born to HBeAg positive mothers than in those born to HBeAg negative mothers (60% vs 25%, p < 0.05). Out of 47 HBsAg-positive mothers, 10 had infants who were HBsAg positive. None of the infants born to HBeAg negative mothers became HBsAg positive but 10/19 (52.6%) of infants born to HBeAg positive mothers became HBsAg positive. This high rate of mother-tochild transmission of HBV in an endemic country is of concern and indicates that routine vaccination program for Lao infants needs strengthening. Keywords: hepatitis B virus, HBsAg, pregnant woman, mother-to-child transmission, Lao PDR INTRODUCTION More than a third of the world s population have been infected with hepatitis B virus (HBV) at some point during their life and half of the estimated 350 million chronic carriers worldwide live Correspondence: Prapan Jutavijittum, Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Tel: +66 (0) 53 935442; Fax: +66 (0) 53 935442 ext 102 E-mail: prapan.j@cmu.ac.th in Asia-Pacific region. Up to 40% of these individuals will die of liver-related complications or progress to hepatocellular carcinoma (Lavanchy, 2004). Mother-to-child transmission (MTCT) is estimated to account for half of chronic HBV infection worldwide (Thio et al, 2015). The main routes of MTCT are through intrauterine transmission, during breast-feeding or other early motherinfant contacts. Without preventative interventions, approximately 40% of infants born to hepatitis B surface anti- 214 Vol 47 No. 2 March 2016

HBV Mother-to-Child Transmission in Lao PDR gen (HBsAg)-positive mothers become chronically infected with HBV. This risk increases to 70-90% in those born to HBsAg and hepatitis E antigen (HBeAg) double-positive mothers. Infants infected at birth have a 90% risk of developing chronic infection. This rate is reduced to 30% if infected between the ages of 1 and 5 years old and to 5-10% if infected after the age of 5 years old (Thio et al, 2015). The risk of infants to become chronically infected can be reduced by a combined early postnatal hepatitis B immunoglobulin (HBIg) treatment and HBV vaccination, but approximately 5-10% of these infants will still become chronically infected (Pan et al, 2012; Zhang et al, 2014). In many countries, an absence of widely available HBIg means that vaccination shortly after birth is the mainstay of HBV prevention and reduction in chronic disease. HBV is endemic in Lao People s Democratic Republic (PDR) where approximately 50% of adults have been exposed to the virus, with a chronic infection rate of up to 10% (Jutavijittum et al, 2007; Black et al, 2014; Jutavijittum et al, 2014). MTCT is believed to be a major route of infection in the country, and, whenever possible, pregnant women are tested upon their first visit to the hospital. Infants receive HBV vaccine shortly after birth and at 6, 10 and 14 weeks of age. The aim of this study was to determine the rate of seroconversion and MTCT among infants born to HBsAg-positive mothers in Lao PDR. MATERIALS AND METHODS Study participants During 2008 and 2009, 3,000 pregnant women attending the antenatal clinic, Mother and Child Hospital, Vientiane, Lao PDR were recruited. All participating mothers were informed of the aims of the study and signed consent forms prior to enrolment. The study was approved by the Lao National Ethics Committee (no. 179) and the Research Ethics Committee, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand (no. 324/2010). Assays Presence of serum HBsAg was tested initially using Onsite HBsAg Rapid Test (CTK Biotech, San Diego, CA) and retested employing both ELISA (EIA; BioChain Institute, Inc, Newark, CA) and automated ARCHITECT HBsAg assay (Abbott Japan, Chiba, Japan). Infant serum HBsAg was tested using BioChain test kit. HBeAg and anti-hbe antibodies were determined using EIA kits (IMMUNIS HBeAg/Ab EIA, Institute of Immunology Co, Ltd, Tokyo, Japan). RESULTS The 3,000 mothers enrolled in the study were aged between 15-49 years old (mean 26.1 ± 4.9 years). Onsite HBsAg Rapid Test was positive in 174 (5.8%) women, mean age of 26.6 ± 4.8 years, and out of 172 available HBsAg-positive serum samples, one was negative when retested using EIA and ARCHITECT assays, indicating 0.5% false positive results of the rapid test. Of the 171 samples 73 (43%) and 86 (50%) were positive for HBeAg and anti-hbe antibodies, respectively. Serum was available from 47 infants, 9-12 months of age born to HBsAg-positive mothers who returned to the hospital for measles vaccination. Ten (21%) infants were HBsAg-positive, all born to HBeAg-positive mothers [10/19 (53%)] (Table 1).Eighteen (38%) infants were anti-hbs negative, with percent born to HBeAg-positive mothers being higher than to HBeAg-negative mothers (58% (11/19) and 25.0% (7/28), respectively, p < 0.05). Vol 47 No. 2 March 2016 215

Table 1 Seroprofile of infants aged 9-12 months born to HBsAg-positive mothers, Vientiane, Lao PDR, 2008-2009. Infant seroprofile HBeAg-positive HBeAg-negative mother mother n (%) n (%) HBsAg+/anti-HBs- 10 (53) 0 (0) HBsAg-/anti-HBs+ 8 (42) 21 (75) HBsAg-/anti-HBs- 1 (5) 7 (25) Total 19 (100) 28 (100) DISCUSSION In this study, we found 5.8% of pregnant mothers attending an antenatal clinic in Vientiane, Lao PDR were positive for HBsAg, a prevalence similar to previous studies in female Lao blood donors and mothers (Jutavijittum et al, 2007; Black et al, 2014; Jutavijittum et al, 2014). The low percent anti-hbs antibodies in infants that we observe at a time where they should have had received 4 doses of HBV-containing vaccines, indicates that the infants had remained unprotected against HBV infection transmitted from their mother during infancy or by other routes later in life. Indeed, 21% were HBsAg-positive, all born to HBsAg- and HBeAg-positive mothers. This represents a MTCT rate of 53% in infants born to HBeAg positive mothers. This rate is substantially higher than the 16.9% of fully vaccinated infants born to HBeAg-positive mothers in a recent study in China, which showed that an additional administration of HBIg to infants reduces this rate to 7.9% (Zhang et al, 2014). Although mothers who were HBeAg positive had high rates of MTCT, it is not known whether this was an independent risk factor or whether it reflected the high level of viremia, which is associated with HBeAg positivity (Xu et al, 2002; Zou et al, 2012). Another risk factor for MTCT includes vaginal delivery (Guo et al, 2013). These risk factors were not addressed in the current study. It also remains unclear whether particular genotypes of HBV had higher propensities to result in MTCT. One study in Japan (Inui et al, 2007) and another in China (Ding et al, 2013) found an association between maternal infection with genotype C virus and MTCT, whilst other studies in China and Canada found no such association (Liu et al, 2009; Singh et al, 2011). In Lao PDR, C and B genotypes are most common, with a high proportion of mixed infections (Olinger et al, 2008; Andernach et al, 2012). The possibility of such profiles impacting on MTCT rate warrants further investigation. The 3-dose HBV vaccine was introduced into Lao PDR national vaccination schedule in 2002 and was improved with the addition of a dose at birth in 2004. A target of 65% is set for the immunization coverage for HBV birth-dose and 80% for the third dose of HBV. However, vaccination coverage remains inadequate in Lao PDR, with only 28% receiving the birth-dose in 2011-2012 and only 78% 216 Vol 47 No. 2 March 2016

HBV Mother-to-Child Transmission in Lao PDR of children less than 1 year old received the DTP-HepB-Hib vaccinations in 2011 (MOH, 2011; ibid, 2012). HBIg is rarely available and thus vaccination remains the basic means of MTCT prevention. A limitation to this study is that vaccination history was not recorded and we are therefore not sure whether the infants had been fully vaccinated against HBV. Nevertheless, the relatively high rate of MTCT of HBV identified in this study, even in a central hospital, is a major challenge to the fulfilment of WHO goal of reducing HBsAg prevalence in Lao PDR to 1% in children over the age of 5 years by the year 2017 (WHO WPRO, 2013). ACKNOWLEDGEMENTS The authors gratefully acknowledge financial support from the Faculty of Medicine, Chiang Mai University and the Faculty of Medicine, Kagawa University. We thank Ms Praijitr Tanan, Blood Bank of Maharaj Nakhon Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University for her excellent technical assistance, and Professor Claude Muller and Dr Antony Black for their comments and suggestions. REFERENCES Andernach IE, Jutavijittum P, Samountry B, et al. A high variability of mixed infections and recent recombinations of hepatitis B virus in Laos. PLOS One 2012; 7: e30245. Black AP, Nouanthong P, Nanthavong N, et al. Hepatitis B virus in the Lao People s Democratic Republic: a cross sectional serosurvey in different cohorts. BMC Infect Dis 2014; 14: 457. Ding Y, Sheng Q, Ma L, Dou X, Chronic HBV infection among pregnant women and their infants in Shenyang, China. Virol J 2013; 10: 17. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-39. Guo Z, Shi XH, Feng YL, et al. Risk factors of HBV intrauterine transmission among HBsAg-positive pregnant women. J Viral Hepat 2013; 20: 317-21. Inui A, Komatsu H, Sogo T, Nagai T, Abe K, Fujisawa T. Hepatitis B virus genotypes in children and adolescents in Japan: before and after immunization for the prevention of mother to infant transmission of hepatitis B virus. J Med Virol 2007; 79: 670-5. Jutavijittum P, Andernach IE, Yousukh A, et al. Occult hepatitis B infections among blood donors in Lao PDR. Vox Sang 2014; 106: 31-7. Jutavijittum P, Yousukh A, Samountry B, et al. Seroprevalence of hepatitis B and C virus infections among Lao blood donors. 2007; 38: 674-9. Lavanchy D, Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107. Liu SL, Dong Y, Zhang L, et al. Influence of HBV gene heterogeneity on the failure of immunization with HBV vaccines in eastern China. Arch Virol 2009; 154: 437-43. Ministry of Health (MOH). National health statistic report FY 2010-2011: contributing to monitor Millenium Development Goals. Viantaine: Department of Planning and International Cooperation, MOH, Lao PDR, 2011. Ministry of Health (MOH). Lao social indicator survey 2011-12. Viantaine: Ministry of Health and Lao Statistics Bureau, 2012. Olinger CM, Jutavijittum P, Hubschen JM, et al. Possible new hepatitis B virus genotype, Southeast Asia. Emerg Infect Dis 2008; 14: 1777-80. Pan CQ, Duan ZP, Bhamidimarri KR, et al. An Vol 47 No. 2 March 2016 217

algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10: 452-9. Singh AE, Plitt SS, Osiowy C, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat 2011; 18: 468-73. Thio CL, Guo N, Xie C, Nelson KE, Ehrhardt S. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis 2015; 15: 981-5. World Health Organization Reginal Office for the Western Pacific. Hepatitis B control through vaccination: setting the target. Regional Committee WPR/RC64/7. Manila: WHO WPRO, 2013. Xu DZ, Yan YP, Choi BC, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002; 67: 20-6. Zhang L, Gui XE, Teter C, et al. Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine. Vaccine 2014; 32: 6091-7. Zou H, Chen Y, Duan Z, Zhang H, Pan C, Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19: e18-25. 218 Vol 47 No. 2 March 2016